Patient Support

In the third part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, notes that in a crowded weight management landscape, marketers play a critical role in combating misinformation by ensuring healthcare providers and patients have clear, accurate information on the safety, efficacy, and access pathways of FDA-approved treatments.

A new JAMA Network Open study highlights how over-the-counter oral contraceptives can reduce barriers to care, especially for uninsured, rural, and adolescent populations, amid shifting federal policies on reproductive health.

By reducing waste, improving forecasting, and strengthening payer negotiations, these technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

As of today, Aug. 27, wholesale distributors must fully comply with the Drug Supply Chain Security Act’s enhanced drug distribution requirements, closing the FDA’s exemption period and advancing efforts to strengthen patient safety and supply chain integrity.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to support safe use, adherence, and management of related chronic health needs.

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

Conversation with chief tech expert explores AI’s rise in the support space—and separating the substance from the noise.

Health systems across the United States are opening large-scale pharmacy service centers to streamline operations, improve inventory control, and ensure timely medication delivery amid drug shortages and rising costs.

Why it’s time to act on passing key bills to boost access for millions.

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect patients from unapproved compounded semaglutide products by targeting pharmacies, telehealth providers, and deceptive marketing practices that compromise safety, mislead consumers, and violate FDA regulations.

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve access, reduce side effects, and support sustainable weight loss.

Amid the growing crisis of pharmacy deserts, these entities are tapping new avenues in care delivery, including the integration of clinical services, nutrition counseling, and real-time patient education.

A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.

These innovations are revolutionizing pharmaceutical packaging by enhancing drug safety, combating counterfeiting, ensuring regulatory compliance, and improving patient adherence across the supply chain.

The acquisition merges eBlu’s automation platform with Knipper’s nationwide distribution network, streamlining benefit verification, prior authorization, and patient onboarding while reducing administrative burdens for specialty providers.

The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.

Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.

New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.

Bruce Leuchter, CEO, Neurvati, explains how industry and advocacy groups can work together to ensure patient and caregiver perspectives continue to inform regulatory decisions—even without a formal public engagement pathway.

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.

In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the federal cap on Medicaid provider taxes could affect access to care for Medicaid patients.

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.